Do analysts rate SLXN or BOLT?

Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 297.26%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bolt Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer SLXN or BOLT?

In the previous week, Bolt Biotherapeutics had 14 more articles in the media than Silexion Therapeutics. MarketBeat recorded 17 mentions for Bolt Biotherapeutics and 3 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 0.80 beat Bolt Biotherapeutics' score of -0.10 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bolt Biotherapeutics 1 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SLXN or OSRH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SLXN or OSRH more profitable?

Silexion Therapeutics has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -563.11% -201.73% OSR -593.15% -8.36% -6.24%

Do analysts prefer CODX or SLXN?

Co-Diagnostics presently has a consensus price target of $67.50, suggesting a potential upside of 6,036.36%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe Co-Diagnostics is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Co-Diagnostics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor CODX or SLXN?

In the previous week, Co-Diagnostics had 3 more articles in the media than Silexion Therapeutics. MarketBeat recorded 6 mentions for Co-Diagnostics and 3 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 0.80 beat Co-Diagnostics' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silexion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SLXN or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 721.92%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SLXN or ERNA more profitable?

Ernexa Therapeutics' return on equity of -305.93% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -563.11% -201.73% Ernexa Therapeutics N/A -305.93% -169.86%

Does the media favor SLXN or ERNA?

In the previous week, Silexion Therapeutics and Silexion Therapeutics both had 3 articles in the media. Silexion Therapeutics' average media sentiment score of 0.80 beat Ernexa Therapeutics' score of 0.29 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ernexa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CDIO or SLXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CDIO or SLXN?

In the previous week, Silexion Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Silexion Therapeutics and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.84 beat Silexion Therapeutics' score of 0.80 indicating that Cardio Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silexion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Silexion Therapeutics (SLXN) Competitors

$0.32 -0.08 (-19.63%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.26 -0.06 (-19.12%)

As of 08:40 AM Eastern

Compare

SLXN vs. BOLT, OSRH, CODX, ERNA, and CDIO

Should you buy Silexion Therapeutics stock or one of its competitors? Silexion Therapeutics's main competitors and comparable companies include Bolt Biotherapeutics (BOLT), OSR (OSRH), Co-Diagnostics (CODX), Ernexa Therapeutics (ERNA), and Cardio Diagnostics (CDIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silexion Therapeutics compare to Bolt Biotherapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

In the previous week, Bolt Biotherapeutics had 14 more articles in the media than Silexion Therapeutics. MarketBeat recorded 17 mentions for Bolt Biotherapeutics and 3 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 0.80 beat Bolt Biotherapeutics' score of -0.10 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bolt Biotherapeutics	1 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 0.8% of Silexion Therapeutics shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Silexion Therapeutics has a beta of -0.36, meaning that its share price is 136% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Silexion Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

Silexion Therapeutics has higher earnings, but lower revenue than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
Bolt Biotherapeutics	$7.70M	0.91	-$33.38M	-$16.44	N/A

Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 297.26%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Bolt Biotherapeutics beats Silexion Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Silexion Therapeutics compare to OSR?

Silexion Therapeutics (NASDAQ:SLXN) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Silexion Therapeutics had 3 more articles in the media than OSR. MarketBeat recorded 3 mentions for Silexion Therapeutics and 0 mentions for OSR. Silexion Therapeutics' average media sentiment score of 0.80 beat OSR's score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silexion Therapeutics	Positive
OSR	Neutral

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 0.8% of Silexion Therapeutics shares are held by insiders. Comparatively, 36.9% of OSR shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Silexion Therapeutics has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
OSR	-593.15%	-8.36%	-6.24%

Silexion Therapeutics has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
OSR	$1.81M	4.76	-$27.06M	-$0.37	N/A

Silexion Therapeutics has a beta of -0.36, indicating that its share price is 136% less volatile than the broader market. Comparatively, OSR has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Summary

Silexion Therapeutics and OSR tied by winning 7 of the 14 factors compared between the two stocks.

How does Silexion Therapeutics compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Co-Diagnostics had 3 more articles in the media than Silexion Therapeutics. MarketBeat recorded 6 mentions for Co-Diagnostics and 3 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 0.80 beat Co-Diagnostics' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silexion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Silexion Therapeutics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Co-Diagnostics' return on equity of -210.99% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%
Silexion Therapeutics	N/A	-563.11%	-201.73%

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by insiders. Comparatively, 0.8% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Silexion Therapeutics has lower revenue, but higher earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$721.39K	10.64	-$46.90M	-$10.32	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A

Co-Diagnostics has a beta of 2.85, meaning that its stock price is 185% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.36, meaning that its stock price is 136% less volatile than the broader market.

Co-Diagnostics presently has a consensus price target of $67.50, suggesting a potential upside of 6,036.36%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe Co-Diagnostics is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Co-Diagnostics beats Silexion Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Silexion Therapeutics compare to Ernexa Therapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Silexion Therapeutics has a beta of -0.36, meaning that its share price is 136% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, meaning that its share price is 161% more volatile than the broader market.

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 0.8% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ernexa Therapeutics' return on equity of -305.93% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

In the previous week, Silexion Therapeutics and Silexion Therapeutics both had 3 articles in the media. Silexion Therapeutics' average media sentiment score of 0.80 beat Ernexa Therapeutics' score of 0.29 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ernexa Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 721.92%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Silexion Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
Ernexa Therapeutics	$580K	10.26	-$14.08M	-$14.35	N/A

Summary

Ernexa Therapeutics beats Silexion Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Silexion Therapeutics compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Silexion Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Silexion Therapeutics	N/A	-563.11%	-201.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cardio Diagnostics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.36, suggesting that its stock price is 136% less volatile than the broader market.

In the previous week, Silexion Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Silexion Therapeutics and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.84 beat Silexion Therapeutics' score of 0.80 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silexion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 0.8% of Silexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cardio Diagnostics has higher revenue and earnings than Silexion Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	568.32	-$6.50M	-$2.92	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A

Summary

Cardio Diagnostics beats Silexion Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Silexion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLXN vs. The Competition

Export

Metric	Silexion Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.18M	$3.98B	$7.31B	$13.28B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.01	13.88	274.10	25.70
Price / Sales	N/A	1,437.48	672.61	90.85
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.04	15.45	10.48	6.32
Net Income	-$11.91M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-17.03%	-1.68%	-0.68%	0.17%
1 Month Performance	-14.23%	-6.15%	-3.18%	-3.27%
1 Year Performance	-99.18%	30.67%	15.13%	5.58%

Silexion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLXN Silexion Therapeutics	1.8817 of 5 stars	$0.32 -19.6%	N/A	-99.1%	$2.18M	N/A	N/A	14	Analyst Revision Gap Down
BOLT Bolt Biotherapeutics	2.3532 of 5 stars	$3.78 -6.2%	$14.50 +283.6%	-34.2%	$7.34M	$4.70M	N/A	90	News Coverage Gap Down
OSRH OSR	0.1914 of 5 stars	$0.20 +15.8%	N/A	-62.5%	$7.20M	$1.81M	N/A	N/A
CODX Co-Diagnostics	2.4459 of 5 stars	$0.99 -13.2%	$67.50 +6,718.2%	-90.8%	$6.91M	$620K	N/A	100	Gap Down
ERNA Ernexa Therapeutics	3.3157 of 5 stars	$3.93 -3.6%	$30.00 +662.6%	-87.9%	$6.42M	$580K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLXN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silexion Therapeutics (SLXN) Competitors

SLXN vs. BOLT, OSRH, CODX, ERNA, and CDIO

How does Silexion Therapeutics compare to Bolt Biotherapeutics?

Summary

How does Silexion Therapeutics compare to OSR?

Summary

How does Silexion Therapeutics compare to Co-Diagnostics?

Summary

How does Silexion Therapeutics compare to Ernexa Therapeutics?

Summary

How does Silexion Therapeutics compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silexion Therapeutics (SLXN) Competitors

SLXN vs. BOLT, OSRH, CODX, ERNA, and CDIO

How does Silexion Therapeutics compare to Bolt Biotherapeutics?

Does the media prefer SLXN or BOLT?

Do insiders & institutionals have more ownership in SLXN or BOLT?

Which has more volatility & risk, SLXN or BOLT?

Is SLXN or BOLT more profitable?

Which has better earnings & valuation, SLXN or BOLT?

Do analysts rate SLXN or BOLT?

Summary

How does Silexion Therapeutics compare to OSR?

Do analysts prefer SLXN or OSRH?

Does the media refer more to SLXN or OSRH?

Do institutionals and insiders hold more shares of SLXN or OSRH?

Is SLXN or OSRH more profitable?

Which has preferable earnings & valuation, SLXN or OSRH?

Which has more risk and volatility, SLXN or OSRH?

Summary

How does Silexion Therapeutics compare to Co-Diagnostics?

Does the media favor CODX or SLXN?

Is CODX or SLXN more profitable?

Do institutionals and insiders have more ownership in CODX or SLXN?

Which has better valuation & earnings, CODX or SLXN?

Which has more volatility and risk, CODX or SLXN?

Do analysts prefer CODX or SLXN?

Summary

How does Silexion Therapeutics compare to Ernexa Therapeutics?

Which has more volatility & risk, SLXN or ERNA?

Do insiders and institutionals hold more shares of SLXN or ERNA?

Is SLXN or ERNA more profitable?

Does the media favor SLXN or ERNA?

Do analysts prefer SLXN or ERNA?

Which has better valuation and earnings, SLXN or ERNA?

Summary

How does Silexion Therapeutics compare to Cardio Diagnostics?

Is CDIO or SLXN more profitable?

Do analysts rate CDIO or SLXN?

Which has more volatility & risk, CDIO or SLXN?

Does the media refer more to CDIO or SLXN?

Do insiders & institutionals believe in CDIO or SLXN?

Which has better earnings and valuation, CDIO or SLXN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools